Niclosamide monohydrate(Synonyms: 氯硝柳胺一水合物; BAY2353 monohydrate)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Niclosamide monohydrate (Synonyms: 氯硝柳胺一水合物; BAY2353 monohydrate)

Niclosamide monohydrate 是一种 STAT3 抑制剂，在 HeLa 细胞中，IC50 值为 0.25 μM，可以抑制 DNA 复制。

Niclosamide monohydrate(Synonyms: 氯硝柳胺一水合物; BAY2353 monohydrate)

Niclosamide monohydrate Chemical Structure

CAS No. : 73360-56-2

规格 价格 是否有货
500 mg ￥400 询问价格 & 货期

* Please select Quantity before adding items.

Niclosamide monohydrate 的其他形式现货产品:

Niclosamide

生物活性

Niclosamide (BAY2353) monohydrate is an orally active antihelminthic agent used for parasitic infections research[1].
Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4].
Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].

IC50 & Target[1]

STAT3

0.25 μM (IC50, in HeLa cells)

体外研究
(In Vitro)

Niclosamide monohydrate (0.6 nM-46 µM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells[3].
Niclosamide monohydrate (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells [4].
Niclosamide monohydrate (10 μM) treatment inhibits virus replication in Vero E6 cells[5].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: BD140A, SW-13 and NCI-H295R cells
Concentration: 0.6 nM-46 µM
Incubation Time:
Result: Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively.

Cell Viability Assay[4]

Cell Line: Hela cells
Concentration: 0.05-5 μM
Incubation Time: 24 hours
Result: Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM.

Cell Viability Assay[5]

Cell Line: Vero E6 cells
Concentration: 10 μM
Incubation Time: 2 days
Result: Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.

体内研究
(In Vivo)

Niclosamide monohydrate (Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Nu+/Nu+ mice injected with NCI-H295R cells[3]
Dosage: 100 mg/kg, 200 mg/kg
Administration: Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks
Result: Showed a 60%-80% inhibition in tumor growth, as compared to the control group.

Clinical Trial

分子量

345.13

Formula

C13H10Cl2N2O5
CAS 号

73360-56-2
中文名称

氯硝柳胺一水合物
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95.

    [2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.

    [3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66.

    [4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9.

    [5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务